Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Wed, 21.07.2021
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, July 21, 2021
Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021
MorphoSys AG (FSE:MOR; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and fi [ … ]
Fri, 16.07.2021
MorphoSys AG
Media Release
MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a resolution to increase the share capital of MorphoSys AG by issu [ … ]
Thu, 15.07.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, July 15, 2021
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
Company Announces Successful Completion of Tender OfferMoves Forward with Strategic Funding Partnership with Royalty Pharma
MorphoSys AG (FSE: MOR; NASDAQ: MOR [ … ]
Thu, 01.07.2021
MorphoSys AG
Media ReleaseMorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Cons [ … ]
Fri, 25.06.2021
MorphoSys AG
Media Release
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the [ … ]
Wed, 16.06.2021
MorphoSys AG
Media Release
MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) ("Constellation") for $34.00 per sha [ … ]
Fri, 04.06.2021
MorphoSys AG
Media ReleaseMorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, Mass., USA and WILMINGTON, Del., [ … ]
Wed, 02.06.2021
MorphoSys AG
MorphoSys to Acquire Constellation Pharmaceuticals
Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209
Bolsters Position in Hematology-Oncology and Expands into Solid Tumors
Best-in-Class Combined Discovery and Development Capabilities Accelerates Ability to Provide New Cancer T [ … ]
Fri, 21.05.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 21, 2021
MorphoSys To Participate in UBS Global Healthcare Conference
MorphoSys AG (FSE & NASDAQ: MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday May 25, 2021 at 7:00 a.m. E [ … ]
Wed, 19.05.2021
MorphoSys AG
Media ReleaseMorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting
PLANEGG/MUNICH, Germany - May 19, 2021 - MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi(R)) development program will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annua [ … ]